TLR4 and pancreatic neoplasm: Zhang et al. [59] found that stimulating TLR-4 and Adenylyl Cyclase-Associated Protein 1(CAP1) receptors with resistin (a factor secreted by macrophages in the tumor microenvironment) can activate the STAT3 pathway and endow pancreatic cancer cells with resistance to drug therapy.